175 related articles for article (PubMed ID: 25716813)
1. [Current Topics on Vitamin D. The role of active forms of vitamin D in regulation of bone remodeling].
Nakamichi Y; Takahashi N
Clin Calcium; 2015 Mar; 25(3):395-402. PubMed ID: 25716813
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of inhibitory action of eldecalcitol, an active vitamin D analog, on bone resorption in vivo.
Takahashi N
J Steroid Biochem Mol Biol; 2013 Jul; 136():171-4. PubMed ID: 23220095
[TBL] [Abstract][Full Text] [Related]
3. Eldecalcitol and calcitriol stimulates 'bone minimodeling,' focal bone formation without prior bone resorption, in rat trabecular bone.
Saito H; Takeda S; Amizuka N
J Steroid Biochem Mol Biol; 2013 Jul; 136():178-82. PubMed ID: 23069645
[TBL] [Abstract][Full Text] [Related]
4. The Vitamin D Receptor in Osteoblast-Lineage Cells Is Essential for the Proresorptive Activity of 1α,25(OH)2D3 In Vivo.
Mori T; Horibe K; Koide M; Uehara S; Yamamoto Y; Kato S; Yasuda H; Takahashi N; Udagawa N; Nakamichi Y
Endocrinology; 2020 Nov; 161(11):. PubMed ID: 32987399
[TBL] [Abstract][Full Text] [Related]
5. Vitamin D endocrine system and osteoclasts.
Takahashi N; Udagawa N; Suda T
Bonekey Rep; 2014; 3():495. PubMed ID: 24605212
[TBL] [Abstract][Full Text] [Related]
6. Vitamin D hormone inhibits osteoclastogenesis in vivo by decreasing the pool of osteoclast precursors in bone marrow.
Shibata T; Shira-Ishi A; Sato T; Masaki T; Masuda A; Hishiya A; Ishikura N; Higashi S; Uchida Y; Saito MO; Ito M; Ogata E; Watanabe K; Ikeda K
J Bone Miner Res; 2002 Apr; 17(4):622-9. PubMed ID: 11918219
[TBL] [Abstract][Full Text] [Related]
7. Bone effects of vitamin D - Discrepancies between in vivo and in vitro studies.
Suda T; Takahashi F; Takahashi N
Arch Biochem Biophys; 2012 Jul; 523(1):22-9. PubMed ID: 22107950
[TBL] [Abstract][Full Text] [Related]
8. Osteoblastic NF-κB pathway is involved in 1α, 25(OH)2D3-induced osteoclast-like cells formation in vitro.
Cong L; Zhang C; Tu G
Int J Clin Exp Pathol; 2015; 8(5):5988-96. PubMed ID: 26191332
[TBL] [Abstract][Full Text] [Related]
9. Vitamin D and bone.
Suda T; Ueno Y; Fujii K; Shinki T
J Cell Biochem; 2003 Feb; 88(2):259-66. PubMed ID: 12520524
[TBL] [Abstract][Full Text] [Related]
10. Effects of 1α,25-(OH)2D3 on the formation and activity of osteoclasts in RAW264.7 cells.
Gu J; Tong XS; Chen GH; Wang D; Chen Y; Yuan Y; Liu XZ; Bian JC; Liu ZP
J Steroid Biochem Mol Biol; 2015 Aug; 152():25-33. PubMed ID: 25864627
[TBL] [Abstract][Full Text] [Related]
11. Effects of two new vitamin D3 derivatives, 22-oxa-1 alpha-25-dihydroxyvitamin D3 (OCT) and 2 beta-(3-hydroxypropoxy)-1 alpha, 25-dihydroxyvitamin D3 (ED-71), on bone metabolism in organ culture.
Sato K; Nishii Y; Woodiel FN; Raisz LG
Bone; 1993; 14(1):47-51. PubMed ID: 8443002
[TBL] [Abstract][Full Text] [Related]
12. New 19-nor-(20S)-1alpha,25-dihydroxyvitamin D3 analogs strongly stimulate osteoclast formation both in vivo and in vitro.
Sato M; Nakamichi Y; Nakamura M; Sato N; Ninomiya T; Muto A; Nakamura H; Ozawa H; Iwasaki Y; Kobayashi E; Shimizu M; DeLuca HF; Takahashi N; Udagawa N
Bone; 2007 Feb; 40(2):293-304. PubMed ID: 17070129
[TBL] [Abstract][Full Text] [Related]
13. Daily administration of eldecalcitol (ED-71), an active vitamin D analog, increases bone mineral density by suppressing RANKL expression in mouse trabecular bone.
Harada S; Mizoguchi T; Kobayashi Y; Nakamichi Y; Takeda S; Sakai S; Takahashi F; Saito H; Yasuda H; Udagawa N; Suda T; Takahashi N
J Bone Miner Res; 2012 Feb; 27(2):461-73. PubMed ID: 22052469
[TBL] [Abstract][Full Text] [Related]
14. [Frontiers in vitamin D; basic research and clinical application. Inhibitory effects of eldecalcitol, an active vitamin D derivative, on bone resorption in vivo].
Harada S; Mizoguchi T; Takahashi N
Clin Calcium; 2011 Nov; 21(11):91-8. PubMed ID: 22040825
[TBL] [Abstract][Full Text] [Related]
15. VDR in Osteoblast-Lineage Cells Primarily Mediates Vitamin D Treatment-Induced Increase in Bone Mass by Suppressing Bone Resorption.
Nakamichi Y; Udagawa N; Horibe K; Mizoguchi T; Yamamoto Y; Nakamura T; Hosoya A; Kato S; Suda T; Takahashi N
J Bone Miner Res; 2017 Jun; 32(6):1297-1308. PubMed ID: 28177161
[TBL] [Abstract][Full Text] [Related]
16. c-Fos protein as a target of anti-osteoclastogenic action of vitamin D, and synthesis of new analogs.
Takasu H; Sugita A; Uchiyama Y; Katagiri N; Okazaki M; Ogata E; Ikeda K
J Clin Invest; 2006 Feb; 116(2):528-35. PubMed ID: 16424941
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory effect of 1,25-dihydroxyvitamin D
Li ZF; Cao LH; Wang Y; Zhang Z; Fan MW; Xu QA
Arch Oral Biol; 2016 Dec; 72():146-156. PubMed ID: 27597534
[TBL] [Abstract][Full Text] [Related]
18. (23S)-25-Dehydro-1{alpha}-hydroxyvitamin D3-26,23-lactone, a vitamin D receptor antagonist that inhibits osteoclast formation and bone resorption in bone marrow cultures from patients with Paget's disease.
Ishizuka S; Kurihara N; Reddy SV; Cornish J; Cundy T; Roodman GD
Endocrinology; 2005 Apr; 146(4):2023-30. PubMed ID: 15618361
[TBL] [Abstract][Full Text] [Related]
19. Vitamin D antagonist, TEI-9647, inhibits osteoclast formation induced by 1alpha,25-dihydroxyvitamin D3 from pagetic bone marrow cells.
Ishizuka S; Kurihara N; Miura D; Takenouchi K; Cornish J; Cundy T; Reddy SV; Roodman GD
J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):331-4. PubMed ID: 15225795
[TBL] [Abstract][Full Text] [Related]
20. Evidence for auto/paracrine actions of vitamin D in bone: 1alpha-hydroxylase expression and activity in human bone cells.
van Driel M; Koedam M; Buurman CJ; Hewison M; Chiba H; Uitterlinden AG; Pols HA; van Leeuwen JP
FASEB J; 2006 Nov; 20(13):2417-9. PubMed ID: 17023519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
